Anthony J. Giovinazzo,
MBA, C. Dir. & A.C.C.
Executive Chairman
Mr. Giovinazzo is an internationally recognized expert in international capital markets access, intellectual property defense, drug development and commercialization, including numerous licensing agreements, with more than 25 years experience in Central Nervous System diseases, primarily Alzheimer’s and Parkinson’s. Most recently, he was a co-inventor and CEO of Cynapsus Therapeutics, a specialty pharmaceutical company that developed an FDA approved sublingual form of apomorphine for Parkinson’s disease; the drug today known as Kynmobi. At Cynapsus, Mr. Giovinazzo built the leadership team, raised US $ 136 million including an over subscribed IPO to NASDAQ and led the negotiations with several pharmaceutical companies that resulted in $ 841 million acquisition of Cynapsus by Sunovion Pharmaceuticals a subsidiary of Sumitomo Dainippon Pharma Co. Ltd., of Japan.
Mr. Giovinazzo is the co-author on a number of peer reviewed publications and an author of several papers focused on strategic and financing issues in the biopharmaceutical industry. He was a Canadian finalist in Life Sciences for the E&Y Entrepreneur of the Year (2014). In 2017 he was the recipient of the Finance Monthly Game Changers award and an inaugural recipient of the Bloom Burton award. He is a Chartered Director and Audit Committee Certified, both from The Directors College, a degree granting affiliate of Mc Master University, Hamilton Canada. He also has completed the Leadership and Strategy in Pharmaceuticals and Biotech, in 2006 from Harvard Business School, Boston, MA; an MBA from IMD, Geneva Switzerland 1986; a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School, York University in Toronto 1984; and a Bachelor of Arts in Economics and Accounting at McMaster University in 1978.